

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AS AT AND FOR NINE MONTH PERIOD ENDED 31 MARCH 2021
(THIRD QUARTER)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Financial Position (Unaudited)
As at 31 March 2021

| Particulars | Amount In BDT | |
|--|-----------------------|-----------------------|
| | 31-Mar-21 | 30-Jun-20 |
| Assets | | |
| Non-Current Assets | 20,828,769,428 | 19,094,525,507 |
| Property, Plant and Equipment | 14,764,138,712 | 14,930,942,237 |
| Right of use Assets | 48,849,098 | 50,347,853 |
| Construction Work in Progress | 3,550,597,829 | 1,651,460,156 |
| Investment in Associates | 319,403,000 | 319,403,000 |
| Other Investments | 2,145,780,788 | 2,142,372,262 |
| Current Assets | 19,751,007,882 | 17,746,581,257 |
| Inventories | 1,654,792,695 | 1,277,620,688 |
| Trade and Other Receivables | 12,605,642,776 | 11,648,659,127 |
| Advances, Deposits & Prepayments | 4,817,491,756 | 3,766,540,017 |
| Fixed Deposit with Banks | 23,357,952 | 19,583,098 |
| Cash and Cash Equivalentents | 649,722,703 | 1,034,178,328 |
| Total Assets | 40,579,777,310 | 36,841,106,765 |
| Shareholders' Equity and Liabilities | | |
| Shareholders' Equity | 18,434,920,853 | 17,963,721,397 |
| Share Capital | 2,340,000,000 | 2,340,000,000 |
| Share Premium | 8,016,892,026 | 8,016,892,026 |
| Reserves | 1,926,228,951 | 1,936,593,119 |
| Retained Earnings | 6,151,799,876 | 5,670,236,252 |
| Non - Controlling Interest | 1,300,195,308 | 1,225,990,411 |
| Total Equity | 19,735,116,161 | 19,189,711,809 |
| Non-Current Liabilities | 15,353,368,795 | 13,204,077,061 |
| Provision for Decommissioning of Assets | 143,405,563 | 143,405,563 |
| Long Term Loan | 15,025,057,699 | 12,871,151,380 |
| Lease Obligation | 41,490,869 | 46,909,046 |
| Deferred Tax Liability | 143,414,664 | 142,611,072 |
| Current Liabilities | 5,491,292,354 | 4,447,317,896 |
| Current portion of Long Term loan | 277,157,666 | 201,882,832 |
| Current Portion of Lease Obligation | 38,980,401 | 38,345,934 |
| Short term loans | 563,952,168 | 565,995,722 |
| Trade and Other Payables | 4,062,913,714 | 3,185,123,864 |
| Employee Benefits | 75,809,074 | 51,864,239 |
| Accrued Expenses | 472,479,331 | 404,105,305 |
| Total Equity & Liabilities | 40,579,777,310 | 36,841,106,765 |
| Number of Shares Used to Compute NAV | 234,000,000 | 234,000,000 |
| Net Asset Value (NAV) Including Revaluation Surplus | 78.78 | 76.77 |
| Net Asset Value (NAV) Excluding Revaluation Surplus | 70.79 | 68.69 |

Sd/-
Sd/-
Sd/-
Sd/-
Sd/-

Chairman
Managing Director
Director
Chief Financial Officer
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Financial Position (Unaudited)
As at 31 March 2021

| Particulars | Amount In BDT | |
|--|-----------------------|-----------------------|
| | 31-Mar-21 | 30-Jun-20 |
| Assets | | |
| Non-Current Assets | 15,222,589,431 | 13,041,155,930 |
| Property, Plant and Equipment | 8,140,958,715 | 7,860,572,660 |
| Right of use Assets | 48,849,098 | 50,347,853 |
| Construction Work in Progress | 3,550,597,829 | 1,651,460,156 |
| Investment in Subsidiaries | 1,017,000,000 | 1,017,000,000 |
| Investment in Associate | 319,403,000 | 319,403,000 |
| Other Investments | 2,145,780,788 | 2,142,372,262 |
| Current Assets | 9,588,651,985 | 8,207,699,634 |
| Inventories | 420,664,862 | 345,170,358 |
| Trade and Other Receivables | 6,561,297,106 | 5,920,737,952 |
| Advances, Deposits & Prepayments | 2,390,785,329 | 1,291,850,015 |
| Fixed Deposit with Banks | 23,357,952 | 19,583,098 |
| Cash and Cash Equivalents | 192,546,736 | 630,358,211 |
| Total Assets | 24,811,241,416 | 21,248,855,564 |
| Shareholders' Equity and Liabilities | | |
| Shareholders' Equity | 12,354,937,628 | 12,367,122,098 |
| Share Capital | 2,340,000,000 | 2,340,000,000 |
| Share Premium | 8,016,892,026 | 8,016,892,026 |
| Reserves | 1,554,215,276 | 1,552,679,134 |
| Retained Earnings | 443,830,327 | 457,550,939 |
| Non-current Liabilities | 10,784,048,880 | 7,176,991,063 |
| Long term loan | 10,599,143,347 | 6,987,470,945 |
| Lease obligation | 41,490,869 | 46,909,046 |
| Deferred tax liability | 143,414,664 | 142,611,072 |
| Current Liabilities | 1,672,254,909 | 1,704,742,403 |
| Current portion long term loan | 277,157,666 | 201,882,832 |
| Current portion of finance lease obligation | 38,980,401 | 38,345,934 |
| Short term loans | 563,952,168 | 565,995,722 |
| Trade and other payables | 446,961,119 | 603,503,932 |
| Employee benefits | 20,794,252 | 24,728,858 |
| Accrued expenses | 324,409,302 | 270,285,125 |
| Total Equity & Liabilities | 24,811,241,416 | 21,248,855,564 |
| Number of Shares Used to Compute NAV | 234,000,000 | 234,000,000 |
| Net Asset Value (NAV) Including Revaluation Surplus | 52.80 | 52.85 |
| Net Asset Value (NAV) Excluding Revaluation Surplus | 46.90 | 46.92 |

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

3

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Nine Month Period Ended 31 March 2021

| Particulars | Amount In BDT | | | | |
|---|------------------------------|------------------------------|----------------------------|----------------------------|----------------------|
| | 1 July 2020 to 31 March 2021 | 1 July 2019 to 31 March 2020 | 1 January to 31 March 2021 | 1 January to 31 March 2020 | |
| Revenue from Net Sales | 28 | 7,762,266,210 | 5,217,128,885 | 2,438,546,717 | 1,453,572,228 |
| Cost of Goods Sold | | (894,270,582) | (846,353,209) | (295,981,647) | (252,261,377) |
| Cost of Power Generation | | (4,987,331,678) | (2,376,631,997) | (1,501,871,600) | (580,253,924) |
| Gross Profit | | 1,880,663,949 | 1,994,143,679 | 640,693,469 | 621,056,927 |
| Operating Expenses | | (781,184,578) | (700,125,153) | (290,809,973) | (229,609,186) |
| General & Administrative Expenses | | (301,077,836) | (271,767,109) | (106,797,465) | (89,176,725) |
| Selling & Distribution Expenses | | (480,106,742) | (428,358,043) | (184,012,507) | (140,432,461) |
| Profit from Operation | | 1,099,479,371 | 1,294,018,527 | 349,883,496 | 391,447,741 |
| Financial Expenses | 29 | (254,895,872) | (520,704,086) | (100,777,919) | (218,412,267) |
| Non Operating Income/ (Loss) | | 29,910,237 | 2,041,264 | 29,137,139 | 585,087 |
| Net Profit from Operation | | 874,493,735 | 775,355,705 | 278,242,717 | 173,620,562 |
| Workers Profit Participation Fund | | (41,642,559) | (11,083,701) | (13,249,653) | (2,271,517) |
| Net Profit before Tax | | 832,851,176 | 764,272,004 | 264,993,064 | 171,349,045 |
| Income Tax | | (67,311,783) | (55,441,387) | (18,107,666) | (12,073,804) |
| Current Tax (Expenses)/Income | 30 | (66,328,650) | (50,012,646) | (16,236,274) | (9,523,733) |
| Deferred Tax (Expenses)/Income | | (983,133) | (5,428,741) | (1,871,392) | (2,550,071) |
| Net Profit after Tax | | 765,539,394 | 708,830,618 | 246,885,398 | 159,275,240 |
| Share of Profit from Associate | | 4,961,600 | 6,113,400 | 1,461,900 | 1,063,200 |
| Net Profit | | 770,500,995 | 714,944,018 | 248,347,298 | 160,338,440 |
| Less: Non Controlling Interest (share of operating profit) | | (74,204,897) | (71,184,624) | (26,043,942) | (16,980,268) |
| Net Profit after Tax before Other Comprehensive Incom | | 696,296,098 | 643,759,394 | 222,303,355 | 143,358,172 |
| Other Comprehensive Income | | (8,983,136) | 57,018,252 | (29,905,101) | 80,422,577 |
| Fair Value Gain of Marketable Securities | | (8,631,077) | (10,485,472) | (12,963,463) | - |
| Fair Value Gain on Investment in Associate | | (891,337) | 65,408,227 | (17,414,284) | 79,992,484 |
| Share of Other Comprehensive Income | | 359,737 | (198,627) | 4,384 | 13,316 |
| Defferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Mkt. securities | | 179,541 | 2,294,124 | 468,262 | 416,777 |
| Total Comprehensive Income Attributable to Ordinary Shareholders | | 687,312,961 | 700,777,646 | 192,398,254 | 223,780,749 |
| Number of Shares Used to Compute EPS | | 234,000,000 | 234,000,000 | 234,000,000 | 234,000,000 |
| Earnings Per Share (EPS) | 31 | 2.98 | 2.75 | 0.95 | 0.61 |

Sd/-
Chairman

Sd-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED

Condensed Statement of Profit or Loss and Other Comprehensive Income (Unaudited)

For Nine Month Period Ended 31 March 2021

| Particulars | Amount In BDT | | | | |
|--|---------------------------------|---------------------------------|-------------------------------|-------------------------------|----------------------|
| | 1 July 2020 to 31 March 2021 | 1 July 2019 to 31 March 2020 | 1 January to 31 March 2021 | 1 January to 31 March 2020 | |
| Revenue from Net Sales | 28.a | 1,956,510,067 | 1,819,111,217 | 662,794,466 | 542,592,976 |
| Cost of Goods Sold | | (894,270,582) | (846,353,209) | (295,981,647) | (252,261,377) |
| Gross Profit | | 1,062,239,484 | 972,758,008 | 366,812,819 | 290,331,599 |
| Operating Expenses | | (737,393,437) | (646,740,744) | (279,309,843) | (211,746,008) |
| General & Administrative Expenses | | (257,286,695) | (218,382,701) | (95,297,336) | (71,313,548) |
| Selling & Distribution Expenses | | (480,106,742) | (428,358,043) | (184,012,507) | (140,432,461) |
| Profit from Operation | | 324,846,047 | 326,017,264 | 87,502,976 | 78,585,591 |
| Financial Expenses | 29.a | (65,730,813) | (95,300,810) | (39,168,209) | (31,468,815) |
| Non Operating Income/ (Loss) | | 29,910,237 | 2,041,264 | 29,137,139 | 585,087 |
| Net Profit from Operation | | 289,025,471 | 232,757,719 | 77,471,906 | 47,701,863 |
| Workers Profit Participation Fund | | (13,763,118) | (11,083,701) | (3,689,138) | (2,271,517) |
| Net Profit before Tax | | 275,262,353 | 221,674,018 | 73,782,768 | 45,430,346 |
| Income Tax | | (67,311,783) | (55,441,387) | (18,107,666) | (12,073,804) |
| Current Tax (Expenses)/Income | 30 | (66,328,650) | (50,012,646) | (16,236,274) | (9,523,733) |
| Deferred Tax (Expenses)/Income | | (983,133) | (5,428,741) | (1,871,392) | (2,550,071) |
| Net Profit after Tax | | 207,950,571 | 166,232,631 | 55,675,102 | 33,356,542 |
| Share of Profit from Associates | | 4,961,600 | 6,113,400 | 1,461,900 | 1,063,200 |
| Net Profit after Tax before Other Comprehensive Income | | 212,912,171 | 172,346,031 | 57,137,002 | 34,419,742 |
| Other Comprehensive Income | | (8,983,136) | 57,018,252 | (29,905,101) | 80,422,577 |
| Fair Value Gain of Marketable Securities | | (8,631,077) | (10,485,472) | (12,963,463) | - |
| Fair Value Gain on Investment in Associate | | (891,337) | 65,408,227 | (17,414,284) | 79,992,484 |
| Share of Other Comprehensive Income | | 359,737 | (198,627) | 4,384 | 13,316 |
| Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Mkt. securities | | 179,541 | 2,294,124 | 468,262 | 416,777 |
| Total Comprehensive Income attribute to Ordinary Shareholders | | 203,929,034 | 229,364,284 | 27,231,900 | 114,842,319 |
| Number of Shares Used to Compute EPS | | 234,000,000 | 234,000,000 | 234,000,000 | 234,000,000 |
| Earnings Per Share (EPS) | 31a | 0.91 | 0.74 | 0.24 | 0.15 |

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Changes in Equity (Unaudited)
For Nine Month Period Ended 31 March 2021

Amount in BDT

| Particulars | Ordinary Share Capital | Share Premium | Reserves | Retained Earnings | Total | Non controlling Interest | Total |
|--|---------------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------------|-----------------------|
| Balance at 01 July 2020 | 2,340,000,000 | 8,016,892,026 | 1,936,593,119 | 5,670,236,252 | 17,963,721,396 | 1,225,990,411 | 19,189,711,808 |
| Net Profit after Tax | - | - | - | 696,296,098 | 696,296,098 | 74,204,897 | 770,500,995 |
| Cash Dividend for the year 2019-2020 | | | | (234,000,000) | (234,000,000) | | (234,000,000) |
| Fair Value Gain /(Loss) on Investment in Associate | | | (891,337) | - | (891,337) | - | (891,337) |
| Fair Value (Loss)/Gain on Marketable Securities | | | (8,631,077) | - | (8,631,077) | - | (8,631,077) |
| Adjustment for sale of Mkt. Securities | | | 17,886,495 | - | 17,886,495 | - | 17,886,495 |
| Share of Other Comprehensive Income | | | 359,737 | - | 359,737 | - | 359,737 |
| Adjustment of Deferred tax on Revaluation Surplus | | | 179,541 | - | 179,541 | - | 179,541 |
| Depreciation on Revaluation Surplus | | | (19,267,527) | 19,267,527 | - | - | - |
| Balance at 31 March 2021 | 2,340,000,000 | 8,016,892,026 | 1,926,228,951 | 6,151,799,876 | 18,434,920,853 | 1,300,195,308 | 19,735,116,161 |

For Nine Month Period Ended 31 March 2020

Amount in BDT

| Particulars | Ordinary Share Capital | Share Premium | Reserves | Retained Earnings | Total | Non controlling Interest | Total |
|--|---------------------------|----------------------|----------------------|----------------------|-----------------------|-----------------------------|-----------------------|
| Balance at 01 July 2019 | 2,340,000,000 | 8,016,892,026 | 1,908,891,010 | 5,328,568,962 | 17,594,351,998 | 1,154,626,813 | 18,748,978,811 |
| Net Profit after Tax | - | - | - | 643,759,394 | 643,759,394 | 71,184,624 | 714,944,018 |
| Cash Dividend for the year 2018-2019 | | | - | (351,000,000) | (351,000,000) | - | (351,000,000) |
| Fair Value Gain /(Loss) on Investment in Associate | | | 65,408,227 | - | 65,408,227 | - | 65,408,227 |
| Fair Value (Loss)/Gain on Marketable Securities | | | (10,485,472) | - | (10,485,472) | - | (10,485,472) |
| Adjustment for sale of Mkt. Securities | | | 47,537 | - | 47,537 | - | 47,537 |
| Share of Other Comprehensive Income | | | (198,627) | - | (198,627) | - | (198,627) |
| Adjustment of Deferred tax on Revaluation Surplus | | | 2,294,124 | - | 2,294,124 | - | 2,294,124 |
| Depreciation on Revaluation Surplus | | | (20,297,380) | 20,297,380 | - | - | - |
| Balance at 31 March 2020 | 2,340,000,000 | 8,016,892,026 | 1,945,659,419 | 5,641,625,736 | 17,944,177,181 | 1,225,811,437 | 19,169,988,618 |

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Changes in Equity (Unaudited)
For Nine Month Period Ended 31 March 2021

| Particulars | Amount in BDT | | | | |
|---|------------------------|----------------------|----------------------|--------------------|-----------------------|
| | Ordinary Share Capital | Share Premium | Reserves | Retained Earnings | Total |
| Balance at 01 July 2020 | 2,340,000,000 | 8,016,892,026 | 1,552,679,134 | 457,550,939 | 12,367,122,099 |
| Net Profit after Tax | - | - | - | 212,912,171 | 212,912,171 |
| Cash Dividend for the year 2019-2020 | - | - | - | (234,000,000) | (234,000,000) |
| Fair Value Gain / (Loss) on Investment in Associate | - | - | (891,337) | - | 891,337 |
| Fair Value (Loss)/Gain on Marketable Securities | - | - | (8,631,077) | - | (8,631,077) |
| Adjustment for sale of Mkt. Securities | - | - | 17,886,495 | - | 17,886,495 |
| Share of Other Comprehensive Income | - | - | 359,737 | - | 359,737 |
| Adjustment of Deferred tax on Revaluation Surplus | - | - | 179,541 | - | 179,541 |
| Depreciation on Revaluation Surplus | - | - | (7,367,218) | 7,367,218 | - |
| Balance at 31 March 2021 | 2,340,000,000 | 8,016,892,026 | 1,554,215,276 | 443,830,327 | 12,354,937,628 |

For Nine Month Period Ended 31 March 2020

| Particulars | Amount in BDT | | | | |
|---|------------------------|----------------------|----------------------|--------------------|-----------------------|
| | Ordinary Share Capital | Share Premium | Reserves | Retained Earnings | Total |
| Balance at 01 July 2019 | 2,340,000,000 | 8,016,892,026 | 1,509,109,947 | 603,094,738 | 12,469,096,711 |
| Net Profit after Tax | - | - | - | 172,346,031 | 172,346,031 |
| Cash Dividend for the year 2018-2019 | - | - | - | (351,000,000) | (351,000,000) |
| Fair Value Gain / (Loss) on Investment in Associate | - | - | 65,408,226 | - | 65,408,226 |
| Fair Value (Loss)/Gain on Marketable Securities | - | - | (10,485,472) | - | (10,485,472) |
| Adjustment for sale of Mkt. Securities | - | - | 47,537 | - | 47,537 |
| Share of Other Comprehensive Income | - | - | (198,627) | - | (198,627) |
| Adjustment of Deferred tax on Revaluation Surplus | - | - | 2,294,124 | - | 2,294,124 |
| Depreciation on Revaluation Surplus | - | - | (8,335,538) | 8,335,538 | - |
| Balance at 31 March 2020 | 2,340,000,000 | 8,016,892,026 | 1,557,840,198 | 432,776,307 | 12,347,508,531 |

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Condensed Consolidated Statement of Cash Flows (Unaudited)

For Nine Month Period Ended 31 March 2021

| Particulars | Amount In BDT | |
|--|---------------------------------|---------------------------------|
| | 1 July 2020 to 31 March 2021 | 1 July 2019 to 31 March 2020 |
| A. Cash Flows from Operating Activities : | | |
| Cash Received from Customers | 7,080,442,856 | 5,153,238,726 |
| Cash Paid to Suppliers | (4,141,530,537) | (3,531,627,449) |
| Cash Payment for Operating Expenses | (1,132,379,179) | (968,899,162) |
| Cash Generated from Operation | 1,806,533,140 | 652,712,114 |
| Income Taxes Paid | (47,689,344) | (14,429,663) |
| Net Cash Generated/(Used) from Operating Activities | 1,758,843,795 | 638,282,451 |
| B. Cash Flows from Investing Activities : | | |
| Acquisition of Property, Plant & Equipment | (678,366,757) | (488,214,812) |
| Capital Work in Progress | (1,899,137,673) | (355,970,711) |
| Investment in Subsidiaries, Associate & Others | (1,236,435,325) | (2,939,778,558) |
| Interest, Dividend & Other Income | 29,910,237 | 2,041,264 |
| Net Cash Received/(Used) from Investing Activities | (3,784,029,518) | (3,781,922,816) |
| C. Cash Flows from Financing Activities : | | |
| Long Term Loan Received/ (Repaid) | 2,229,181,154 | 4,672,110,484 |
| Short Term Loan Received/ (Repaid) | 32,468,483 | (5,894,245) |
| Lease obligation | (4,783,710) | (4,346,392) |
| Financial expenses paid | (259,208,292) | (743,659,968) |
| Dividend paid | (356,927,538) | (229,095,737) |
| Net Cash Received/(Used) from Financing Activities | 1,640,730,097 | 3,689,114,143 |
| Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C) | (384,455,625) | 545,473,779 |
| Cash & Cash Equivalents at the beginning of the period | 1,034,178,328 | 92,187,429 |
| Cash & Cash Equivalents at the end of the period | 649,722,703 | 637,661,207 |
| Number of Shares Used to Compute NOCFPS | 234,000,000 | 234,000,000 |
| Operating Cash Flow Per Share | 7.52 | 2.73 |

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Cash Flows (Unaudited)
For Nine Month Period Ended 31 March 2021

| Particulars | Amount In BDT | |
|---|---------------------------------|---------------------------------|
| | 1 July 2020 to 31 March 2021 | 1 July 2019 to 31 March 2020 |
| A. Cash Flows from Operating Activities : | | |
| Cash Received from Customers | 1,958,888,275 | 1,827,242,553 |
| Cash paid to Suppliers | (693,092,360) | (735,876,694) |
| Cash Payment for Operating Expenses | (1,132,379,179) | (968,899,162) |
| Cash Generated from Operation | 133,416,736 | 122,466,697 |
| Income Taxes Paid | (47,689,344) | (14,429,663) |
| Net Cash Generated/(Used) from Operating Activities | 85,727,391 | 108,037,034 |
| B. Cash Flows from Investing Activities : | | |
| Acquisition of Property, Plant & Equipment | (675,337,727) | (487,770,578) |
| Capital Work in Progress | (1,899,137,673) | (355,970,711) |
| Investment in Subsidiaries, Associate, Securities & Others | (1,236,435,325) | (69,944,141) |
| Interest, Dividend & Other Income | 29,910,237 | 2,041,264 |
| Net Cash Received/(Used) from Investing Activities | (3,781,000,488) | (911,644,165) |
| C. Cash Flows from Financing Activities : | | |
| Long Term Loan Received/ (Repaid) | 3,686,947,236 | 1,216,522,529 |
| Short Term Loan Received/ (Repaid) | (2,043,554) | (4,934,697) |
| Lease obligation | (4,783,710) | (4,346,392) |
| Dividend paid | (356,927,538) | (229,095,737) |
| Interest Paid | (65,730,813) | (95,300,810) |
| Net Cash Received/(Used) from Financing Activities | 3,257,461,621 | 882,844,894 |
| Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) | (437,811,475) | 79,237,763 |
| Cash & Cash Equivalents at the beginning of the period | 630,358,211 | 30,728,806 |
| Cash & Cash Equivalents at the end of the period | 192,546,736 | 109,966,569 |
| Number of Shares Used to Compute NOCFPS | 234,000,000 | 234,000,000 |
| Operating Cash Flow Per Share | 33a.1 0.37 | 0.46 |

Sd- Chairman
Sd- Managing Director
Sd- Director
Sd- Chief Financial Officer
Sd- Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Selected Explanatory Notes to the Condensed Consolidated Financial Statements
For Nine Month Period Ended 31 March 2021 (Third Quarter)

1 Reporting Entity

1.1 Background of the Entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154, Tejgaon I/ A, Dhaka-1208, Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.2 Nature of Business

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health- related consumer products.

1.3 Subsidiary Companies

1.3.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat, Dhaka with machineries and equipment supplied by Wartsila OY, Finland. The generated output of 105 MW electricity is being regularly supplied to national grid. Orion Pharma Ltd. holds 95% of equity share of this company directly.

1.3.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj with machineries and equipment supplied by Wartsila OY, Finland. The generated output of 105 MW electricity is being regularly supplied to national grid. Orion Pharma Ltd. holds 67% of equity share of this Company.

1.4 Associate Company

Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

2 Basis of Preparation

2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), in particular International Accounting Standard (IAS) 34: *Interim Financial Reporting*, the Companies Act 1994, Securities and Exchange Rules 1987 and other applicable laws and regulations.

2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting,' these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT), which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover three month period from 1 July 2020 to 31 March 2021.

2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on **June 30, 2021** for publication.

2.7 Events after the reporting period

Information regarding subsidiary companies

Orion Power Meghnaghat Limited and Dutch Bangla Power & Associates Limited are the subsidiary Companies of Orion Pharma Limited. The contract between Bangladesh Power Development Board and Orion Power Meghnaghat Limited for supplying electricity to the national grid has expired in May 2021 and Dutch Bangla Power & Associates Limited will be expired in July 2021.

The company applied to the Government of Bangladesh to extend the contract period for supplying electricity for another 5 (five) years and the renewal of contract of both power plants are under process.

3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2020.

4 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018.

5 Acquisition of Property, Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

| SL No. | Particulars | Amount in Taka | |
|--------|---------------------------|--------------------|--------------------|
| | | 31-Mar-21 | 31-Mar-20 |
| i | Land & Land Development | 37,926,290 | - |
| ii | Factory & Office Building | 255,218,137 | - |
| iii | Plant & Machinery | 344,156,761 | 464,457,823 |
| iv | Furniture & Fixtures | 10,873,025 | 9,390,291 |
| v | Office Equipment | 7,319,490 | 11,694,697 |
| vi | Vehicles | 2,350,000 | 2,672,000 |
| | Total | 657,843,703 | 488,214,812 |

| SL No. | Particulars | Amount in Taka | |
|-------------|--|-----------------------|-----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 11.2 | Investment in non-quoted shares | | |
| | Orion Power Khulna Limited. | 500,000 | 500,000 |
| | Orion Power Dhaka Limited. | 500,000 | 500,000 |
| | ICB Islami Bank Limited | 246,000 | 246,000 |
| | Orion Infrastructure Limited. | 2,117,209,676 | 2,117,209,676 |
| | | 2,118,455,676 | 2,118,455,676 |
| 12. | Inventories | | |
| | Raw materials | 170,414,134 | 145,426,337 |
| | Packing materials | 55,778,420 | 68,227,685 |
| | Work-in-process | 13,499,422 | 17,129,910 |
| | Finished goods | 113,373,132 | 75,769,179 |
| | Printing Stationeries | 1,834,085 | 2,826,678 |
| | Promotional materials | 6,644,092 | 6,114,954 |
| | Goods in transit | 216,468,109 | 434,800,503 |
| | Spare parts | 480,711,356 | 340,123,417 |
| | Inventory HFO & LFO | 596,069,945 | 187,202,025 |
| | | 1,654,792,695 | 1,277,620,688 |
| 12.a | Inventories | | |
| | Raw materials | 170,414,134 | 145,426,337 |
| | Packing materials | 55,778,420 | 68,227,685 |
| | Work-in-process | 13,499,422 | 17,129,910 |
| | Finished goods | 113,373,132 | 75,769,179 |
| | Printing Stationeries | 1,834,085 | 2,826,678 |
| | Promotional materials | 6,644,092 | 6,114,954 |
| | Goods in transit | 59,121,578 | 29,675,615 |
| | | 420,664,862 | 345,170,358 |
| 13. | Trade & other receivables | | |
| | Trade receivables | 3,343,652,175 | 2,661,828,822 |
| | Other receivables (Note-13.1) | 9,261,990,601 | 8,986,830,305 |
| | | 12,605,642,776 | 11,648,659,127 |

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

| | | |
|----------------|----------------------|----------------------|
| Below 180 days | 3,343,652,175 | 2,661,828,822 |
| Above 180 days | - | - |
| | 3,343,652,175 | 2,661,828,822 |

| SL. No. | Particulars | Amount in Taka | |
|---------|---|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| I | Trade receivables considered good in respect of which the company is fully secured | 3,343,652,175 | 2,661,828,822 |
| II | Trade receivables considered good in respect of which the company holds no security other than the debtor personal security | - | - |
| III | Trade receivables considered doubtful or bad | - | - |
| IV | Trade receivables due by any director or other officer of the company | - | - |
| V | Trade receivables due by common management | - | - |
| VI | The maximum amount of receivable due by any director or other officer of the | - | - |
| | Total | 3,343,652,175 | 2,661,828,822 |

| SL No. | Particulars | Amount in Taka | |
|-------------|---|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 13.1 | Other receivables | | |
| | Claim receivables, insurance & others | 3,500,404 | 3,064,643 |
| | Divided receivable | - | 4,430,000 |
| | Interest on FDR | 248,655 | 165,532 |
| | Other receivables | 855,919,008 | 209,566,675 |
| | Current account with other related companies (Note. 13.1.1) | 8,402,322,534 | 8,769,603,456 |
| | | 9,261,990,601 | 8,986,830,305 |

13.1.1 Current account with other related companies

| | | |
|--------------------------------------|----------------------|----------------------|
| Noakhali Gold Food Ltd. | 33,129,928 | 33,129,928 |
| Orion Properties Ltd. | 33,871,089 | 33,871,089 |
| Orion Gas Limited | 49,200,000 | 49,200,000 |
| Orion Power Khulna Ltd | 1,029,967,694 | 1,029,967,694 |
| Orion Power Dhaka Ltd | 2,431,298,916 | 2,431,298,916 |
| Jafflong Tea Company | 2,408,371 | 2,408,371 |
| Orion Agro Product | 240,118,758 | 240,118,758 |
| Interior Accom Consortium Limited | 122,338,459 | 155,495,459 |
| Digital Power & Associate Ltd. | 680,104,474 | 444,684,971 |
| Orion Footwear Ltd. | 108,662,162 | 107,775,395 |
| Orion Oil & Shipping Ltd. | 133,927,696 | 215,230,919 |
| Panbo Bangla Mashroom Ltd. | 115,006,570 | 115,006,570 |
| Orion Power Unit 2 Dhaka Ltd. | 1,759,046,772 | 2,178,093,169 |
| Orion Home Appliance Ltd. | 7,848,000 | 47,848,000 |
| Orion Knit Textiles Ltd. | 220,544,115 | 220,544,115 |
| Orion Hospitals Ltd. | 17,300,000 | 16,500,000 |
| Orion Power Rupsha Ltd. | 264,322,069 | 305,033,401 |
| Orion Power Sonargaon Ltd. | 1,011,727,461 | 1,001,896,701 |
| Energion Renewable (BD) Ltd. | 1,500,000 | 1,500,000 |
| Orion Quaderia Textiles Limited | 130,000,000 | 130,000,000 |
| Horizon Media & Publications Limited | 10,000,000 | 10,000,000 |
| | 8,402,322,534 | 8,769,603,456 |

13.a Trade & other receivables

| | | |
|----------------------------------|----------------------|----------------------|
| Trade receivables | 153,273,909 | 155,652,117 |
| Other receivables (Note - 13a.1) | 6,408,023,197 | 5,765,085,835 |
| | 6,561,297,106 | 5,920,737,952 |

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

| | | |
|----------------|--------------------|--------------------|
| Below 180 days | 153,273,909 | 155,652,117 |
| Above 180 days | - | - |
| | 153,273,909 | 155,652,117 |

| SL No | Particulars | Amount in Taka | |
|-------|---|--------------------|--------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| I | Trade receivables considered good in respect of which the company is fully secured | 153,273,909 | 155,652,117 |
| II | Trade receivables considered good in respect of which the company holds no security other than the debtor personal security | | - |
| III | Trade receivables considered doubtful or bad | | - |
| IV | Trade receivables due by any director or other officer of the company | | - |
| V | Trade receivables due by common management | | - |
| VI | The maximum amount of receivable due by any director or other officer of the | | - |
| | Total | 153,273,909 | 155,652,117 |

| SL No. | Particulars | Amount in Taka | |
|----------------|--|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 13a.1 | Other receivables | | |
| | Claim receivables, insurance & others | 3,500,404 | 3,064,643 |
| | Divided receivable | - | 4,430,000 |
| | Interest on FDR | 248,655 | 165,532 |
| | Other receivables | 855,919,008 | 209,566,675 |
| | Current account with subsidiaries (13a.1.1) | 369,895,908 | 369,399,764 |
| | Current account with other related companies (13a.1.2) | 5,178,459,222 | 5,178,459,222 |
| | | 6,408,023,197 | 5,765,085,835 |
| 13a.1.1 | Current account with subsidiaries | | |
| | Dutch Bangla Power & Associates Limited. | 369,895,908 | 369,399,764 |
| | | 369,895,908 | 369,399,764 |
| 13a.1.2 | Current account with other related companies | | |
| | Orion Properties Ltd. | 20,331,532 | 20,331,532 |
| | Orion Power Khulna Ltd. | 986,021,913 | 986,021,913 |
| | Orion Power Dhaka Ltd. | 2,176,293,707 | 2,176,293,707 |
| | Interior Accom Consortium Ltd. | 107,995,459 | 107,995,459 |
| | Orion Agro Product Ltd. | 232,265,920 | 232,265,920 |
| | Orion Power Unit -2 Dhaka Ltd. | 1,358,708,776 | 1,358,708,776 |
| | Orion Power Rupsha Ltd. | 186,800,000 | 186,800,000 |
| | Digital Power & Associates Ltd. | 97,341,915 | 97,341,915 |
| | Orion Hospitals Ltd. | 12,700,000 | 12,700,000 |
| | | 5,178,459,222 | 5,178,459,222 |
| 14. | Advances, deposits and prepayments | | |
| | Advances: | | |
| | Advance income tax (Note-14.1) | 159,552,889 | 133,033,785 |
| | Advance imprest money | 212,500 | 43,000 |
| | Advance motor cycle | 15,264,559 | 14,630,196 |
| | Advance - car loan | 2,364,231 | 2,976,934 |
| | Collection advance | 5,694,861 | 5,455,130 |
| | Advance to C&F agents | 21,254,056 | 1,382,576 |
| | Advance paid to Suppliers & Others | 825,464,294 | 225,604,358 |
| | Advance against land purchase | 568,935,000 | 325,000,000 |
| | Advance against material loan | - | 2,381,414 |
| | Advance office rent | 6,208,417 | 6,898,673 |
| | Advance to Employee | 83,601,572 | 3,867,815 |
| | Advance for machinery - BHF Bank | 580,964,815 | 640,756,566 |
| | Advance for Machinery CFIS-SBLC | 39,626,747 | - |
| | Advance Mobile set purchase | 2,895,224 | - |
| | Other advance | 1,958,116,925 | 2,037,716,920 |
| | | 4,270,156,089 | 3,399,747,367 |
| | Deposits: | | |
| | Earnest money | 365,000 | 455,000 |
| | Security deposit | 42,658,325 | 45,422,826 |
| | Bank Guarantee Margin | 127,250,731 | 69,712,449 |
| | L/C margin | 297,829,267 | 191,656,453 |
| | Lease deposit | 14,694,360 | 15,021,334 |
| | | 482,797,683 | 322,268,062 |
| | Prepayments: | | |
| | Insurance premium | 1,656,194 | 953,003 |
| | Bank gurantee,commission & charge | 62,774,040 | 43,571,585 |
| | Deferred expenses | 107,750 | - |
| | | 64,537,984 | 44,524,588 |
| | | 4,817,491,756 | 3,766,540,017 |

| SL No. | Particulars | Amount in Taka | |
|--------------|---|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 14.1 | Advance income tax | | |
| | Opening balance | 133,033,785 | 104,849,700 |
| | Add: Addition during the year | 26,519,103 | 28,184,084 |
| | | 159,552,889 | 133,033,784 |
| | Less: Adjustment of assessment for previous | - | - |
| | Closing balance | 159,552,889 | 133,033,785 |
| 14.a | Advances, deposits & prepayments | | |
| | Advances: | | |
| | Advance income tax (Note -14a.1) | 158,089,824 | 131,716,484 |
| | Advance imprest money | 212,500 | 43,000 |
| | Motor cycle advance | 15,264,559 | 14,630,196 |
| | Advance - car loan | 2,364,231 | 2,976,934 |
| | Collection advance | 5,694,861 | 5,455,130 |
| | Advance to C&F agents | 21,254,056 | 1,382,576 |
| | Advance paid to Suppliers & Others | 45,230,540 | - |
| | Advance against land purchase | 568,935,000 | 325,000,000 |
| | Advance against material loan | - | 2,381,414 |
| | Advance office rent | 6,208,417 | 6,898,673 |
| | Advance to Employees | 82,335,092 | - |
| | Machinery & equipment | 602,056,725 | 75,093,648 |
| | Electrical equipment | 1,797,592 | 359,486 |
| | Construction | 63,453,322 | 31,008,033 |
| | Advance for machinery - BHF Bank | 580,964,815 | 640,756,566 |
| | Advance for Machinery CFIS-SBLC | 39,626,747 | - |
| | Advance Mobile set purchase | 2,895,224 | - |
| | | 2,196,383,504 | 1,237,702,141 |
| | Deposits | | |
| | Earnest money | 365,000 | 455,000 |
| | Security deposit | 42,658,325 | 34,911,306 |
| | Bank guarantee | 9,441,540 | - |
| | L/C Margin | 127,700,000 | 4,217,634 |
| | Lease deposit | 14,236,960 | 14,563,934 |
| | | 194,401,825 | 54,147,874 |
| | | 2,390,785,329 | 1,291,850,015 |
| 14a.1 | Advance income tax | | |
| | Opening balance | 131,716,484 | 103,789,126 |
| | Addition during the year | 26,373,340 | 27,927,358 |
| | Closing balance | 158,089,824 | 131,716,484 |
| 15. | Fixed deposit with banks | | |
| | Social Islami Bank Limited., Principal Branch, Dhaka. | 8,852,027 | 8,512,435 |
| | Agrani Bank Ltd. | 14,505,926 | 11,070,663 |
| | | 23,357,952 | 19,583,098 |
| 16. | Cash & cash equivalents | | |
| | Cash in hand (Note -16.1) | 28,666,778 | 10,613,804 |
| | Cash at B/O account (Note -16.2) | 14,473 | 93,022 |
| | | 28,681,251 | 10,706,826 |
| | Balance with banks on account | | |
| | Current account | 497,886,506 | 420,797,288 |
| | Short term deposit account | 123,154,946 | 602,674,214 |
| | | 621,041,452 | 1,023,471,502 |
| | | 649,722,703 | 1,034,178,328 |

| SL No. | Particulars | Amount in Taka | |
|--------------|---|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 16.1 | Cash in hand | | |
| | Head office | 26,746,778 | 4,972,534 |
| | Depot office | 1,920,000 | 5,641,270 |
| | | 28,666,778 | 10,613,804 |
| 16.2 | Cash at B/O account | | |
| | Bank Asia Securities Limited. | (2,361) | 89,350 |
| | Jahan Securities Limited. | 2,424 | 2,874 |
| | LankaBangla Securities Ltd. | 14,410 | 798 |
| | | 14,473 | 93,022 |
| 16.a | Cash and cash equivalents | | |
| | Cash in hand (Note -16a.1) | 24,969,772 | 8,445,688 |
| | Cash at B/O account (Note -16a.2) | 14,473 | 93,022 |
| | | 24,984,245 | 8,538,710 |
| | Cash at Bank: | | |
| | Current account | 44,407,545 | 19,145,287 |
| | Short term deposit account | 123,154,946 | 602,674,214 |
| | | 167,562,491 | 621,819,501 |
| | | 192,546,736 | 630,358,211 |
| 16a.1 | Cash in hand | | |
| | Head office - central cash & main cash | 23,049,772 | 2,804,418 |
| | Depot office - petty cash | 1,920,000 | 5,641,270 |
| | | 24,969,772 | 8,445,688 |
| 16a.2 | Cash at B/O account | | |
| | Bank Asia Securities Limited | (2,361) | 89,350 |
| | Jahan Securities Limited | 2,424 | 2,874 |
| | LankaBangla Securities Ltd. | 14,410 | 798 |
| | | 14,473 | 93,022 |
| 17. | Share capital | | |
| | Authorized capital | | |
| | 500,000,000 ordinary shares of Tk. 10 each | 5,000,000,000 | 5,000,000,000 |
| | Issued, subscribed and paid-up capital | | |
| | 234,000,000 ordinary shares of Tk. 10 each | 2,340,000,000 | 2,340,000,000 |

Shareholding position of the company

| Range of Shareholding | Number of Shareholders | Number of Shares | % of holding | |
|-------------------------|------------------------|------------------|--------------|-------------|
| | | | 31-Mar-21 | 30-Jun-20 |
| Up to 500 Shares | 26,030 | 3,114,360 | 1.33% | 1.37% |
| 501 to 5,000 Shares | 6,742 | 13,314,426 | 5.69% | 4.43% |
| 5001 to 10,000 Shares | 1,214 | 8,899,414 | 3.80% | 2.92% |
| 10,001 to 20,000 Shares | 687 | 9,989,406 | 4.27% | 3.05% |
| 20,001 to above | 605 | 198,682,394 | 84.91% | 88.23% |
| Total | 35,278 | 234000000 | 100% | 100% |

| SL No. | Particulars | | Amount in Taka | |
|----------------------------|------------------------|------------------|----------------|-------------|
| | | | 31-Mar-21 | 30-Jun-20 |
| Categories of shareholders | Number of Shareholders | Number of Shares | % of holding | |
| | | | 31-Mar-21 | 30-Jun-20 |
| Sponsors | 5 | 74,841,600 | 31.98% | 31.98% |
| Foreign Investor | 152 | 2,671,594 | 1.14% | 1.65% |
| Financial institutions | 393 | 93,108,947 | 39.79% | 46.74% |
| General public | 34,728 | 63,377,859 | 27.08% | 19.63% |
| Total | 35,278 | 234000000 | 100% | 100% |

| Orion Power Meghnaghat Limited | Number of Shares | Face Value | % of holding | |
|--------------------------------|--------------------|----------------------|--------------|-------------|
| | | | 31-Mar-21 | 30-Jun-20 |
| Orion Pharma Limited | 95,000,000 | 950,000,000 | 95.00% | 95.00% |
| Integral Energy Limited | 3,000,000 | 30,000,000 | 3.00% | 3.00% |
| Jafflong Tea Company Limited | 500,000 | 5,000,000 | 0.50% | 0.50% |
| Mr. Mohammad Obaidul Karim | 500,000 | 5,000,000 | 0.50% | 0.50% |
| Mr. Salman Obaidul Karim | 600,000 | 6,000,000 | 0.60% | 0.60% |
| Mrs. Arzuda Karim | 350,000 | 3,500,000 | 0.35% | 0.35% |
| Haarhuis Generation B.V. | 50,000 | 500,000 | 0.05% | 0.05% |
| Total | 100,000,000 | 1,000,000,000 | 100% | 100% |

| Dutch Bangla Power & Associates Limited | Number of Shares | Face Value | % of holding | |
|---|-------------------|--------------------|--------------|-------------|
| | | | 31-Mar-21 | 30-Jun-20 |
| Orion Pharma Limited | 6,700,000 | 67,000,000 | 67.00% | 67.00% |
| Shenzhen Nanshan Power Co. Ltd. | 50,000 | 500,000 | 0.50% | 0.50% |
| Mohammad Obaidul Karim | 100,000 | 1,000,000 | 1.00% | 1.00% |
| Salman Obaidul Karim | 3,087,500 | 30,875,000 | 30.88% | 30.88% |
| Orion Tea Company Ltd. | 50,000 | 500,000 | 0.50% | 0.50% |
| Jafflong Tea Co. Ltd. | 2,500 | 25,000 | 0.03% | 0.03% |
| Mrs. Arzuda Karim | 10,000 | 100,000 | 0.10% | 0.10% |
| Total | 10,000,000 | 100,000,000 | 100% | 100% |

18. Reserves

| | | |
|---|----------------------|----------------------|
| Fair value gain/(loss) on investment in associate (Note -18.1) | 236,284,604 | 237,175,941 |
| Fair value gain /(loss) on marketable securities (Note -18.2) | (13,760,182) | (22,090,059) |
| Share of other comprehensive income of associate (Note - 18.3) | 6,107,866 | 5,748,129 |
| Revaluation surplus on property, plant and equipment (Note -18.4) | 1,697,596,663 | 1,715,759,107 |
| | 1,926,228,951 | 1,936,593,119 |

18.1 Fair value gain on investment in associate

| | | |
|---|--------------------|--------------------|
| Opening balance | 237,175,941 | 173,844,211 |
| Fair value gain/ (loss) during the year | (891,337) | 63,331,730 |
| | 236,284,604 | 237,175,941 |

18.2 Fair value gain/(loss) on marketable securities

| | | |
|---|---------------------|---------------------|
| Opening balance | (22,090,059) | (12,022,989) |
| Adjustment of sale of marketable securities | 17,886,495 | 47,987 |
| Fair value gain/(loss) on marketable securities (Note - 18.2.1) | (8,631,077) | (11,233,620) |
| Transferred to deferred tax assets/(liabilities) | (925,542) | 1,118,563 |
| | (13,760,182) | (22,090,059) |

| SL No. | Particulars | Amount in Taka | |
|----------------|--|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 18.2.1 | Fair value gain/(loss) on marketable securities during the year | | |
| | Unrealized gain/(loss) position (closing) | (15,289,090) | (24,544,509) |
| | Unrealized gain/(loss) position (opening) | (24,544,509) | (13,358,875) |
| | Total change during the year | 9,255,418 | (11,185,633) |
| | Fair value adjustment for sale of securities (realized loss) | (17,886,495) | (47,987) |
| | Unrealized gain/(loss) during the year | (8,631,077) | (11,233,620) |
| 18.3 | Share of other comprehensive income | | |
| | Opening balance | 5,748,129 | 5,996,659 |
| | Add: Addition during the year | 359,737 | (248,530) |
| | | 6,107,866 | 5,748,129 |
| 18.4 | Revaluation surplus on property, plant & equipment | | |
| | Opening balance | 1,715,759,107 | 1,741,073,129 |
| | Adjustment during the year to retained earnings for depreciation | (19,267,527) | (26,981,129) |
| | Adjustment of deferred tax on revaluation surplus | 1,105,083 | 1,667,108 |
| | | 1,697,596,663 | 1,715,759,107 |
| 18.a | Reserve | | |
| | Fair value gain on investment in associates (Note - 18a.1) | 236,284,604 | 237,175,941 |
| | Fair value gain/(loss) on marketable securities (Note - 18a.2) | (13,760,181) | (22,090,058) |
| | Share of other comprehensive income (Note - 18a.3) | 6,107,866 | 5,748,128 |
| | Revaluation surplus on property, plant & equipment (Note - 18a.4) | 1,325,582,987 | 1,331,845,122 |
| | | 1,554,215,276 | 1,552,679,134 |
| 18a.1 | Fair value gain on investment in associates | | |
| | Opening balance | 237,175,941 | 173,844,211 |
| | Fair value gain/(loss) during the year | (891,337) | 63,331,730 |
| | | 236,284,604 | 237,175,941 |
| 18a.2 | Fair value gain/(loss) on marketable securities | | |
| | Opening balance | (22,090,058) | (12,022,988) |
| | Adjustment of sale of marketable securities | 17,886,495 | 47,987 |
| | Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1) | (8,631,077) | (11,233,620) |
| | Transferred to deferred tax assets/(liabilities) | (925,542) | 1,118,563 |
| | | (13,760,181) | (22,090,058) |
| 18a.2.1 | Fair value gain/(loss) on marketable securities during the year | | |
| | Unrealized gain/(loss) position (closing) | (15,289,090) | (24,544,509) |
| | Unrealized gain/(loss) position (opening) | (24,544,509) | (13,358,875) |
| | Fair value adjustment for sale of securities realized gain/(loss) | (17,886,495) | (47,987) |
| | Unrealized gain/(loss) during the year | (8,631,077) | (11,233,620) |
| 18a.3 | Share of other comprehensive income | | |
| | Opening balance | 5,748,128 | 5,996,659 |
| | Add: Addition during the year | 359,737 | (248,530) |
| | | 6,107,866 | 5,748,128 |
| 18a.4 | Revaluation surplus on property, plant & equipment | | |
| | Opening balance | 1,331,845,122 | 1,341,292,066 |
| | Adjustment during the year to retained earnings for depreciation | (7,367,218) | (11,114,051) |
| | Adjustment of deferred tax on revaluation surplus | 1,105,083 | 1,667,108 |
| | | 1,325,582,987 | 1,331,845,122 |

| SL No. | Particulars | Amount in Taka | |
|---|---|-----------------------|-----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 19. Retained earnings | | | |
| | Opening balance | 5,670,236,252 | 5,328,568,962 |
| | Net profit after tax | 696,296,098 | 665,686,161 |
| | Dividend for the year | (234,000,000) | (351,000,000) |
| | Adjustment for depreciation on revaluation surplus | 19,267,527 | 26,981,129 |
| | | 6,151,799,876 | 5,670,236,252 |
| 19.a Retained Earnings | | | |
| | Opening balance | 457,550,939 | 603,094,738 |
| | Net profit after tax | 212,912,171 | 194,342,150 |
| | Dividend for the year | (234,000,000) | (351,000,000) |
| | Adjustment for depreciation on revaluation surplus | 7,367,218 | 11,114,051 |
| | | 443,830,327 | 457,550,939 |
| 20. Non-controlling interest | | | |
| | Opening balance | 1,225,990,411 | 1,154,626,813 |
| | Share of operating profit | 74,204,897 | 71,363,599 |
| | Closing balance | 1,300,195,308 | 1,225,990,411 |
| 21 Syndicated loan and other long term loans | | | |
| | Mashreq bank PSC | 4,425,914,352 | 5,883,680,435 |
| | Meridian finance & Investment Ltd. | 5,391,952 | 13,356,974 |
| | Phoenix Finance & Investment Ltd. | 213,219,990 | 188,353,872 |
| | Agrani Bank Ltd. -BMRE | 3,578,186,261 | 3,078,758,648 |
| | Social Islami Bank Ltd | 1,000,605,285 | 938,069,748 |
| | AL-Arafa Islami Bank Ltd. | 1,870,458,262 | 1,776,578,444 |
| | ODDO BHF AG Finance | 840,105,642 | 576,109,548 |
| | Rupali Bank Ltd. | 673,268,517 | 618,126,543 |
| | SBLC-Cargill Financial Services International(CFSI) | 2,536,109,550 | - |
| | Term Loan Rupali Bank Ltd-UPAS LC | 87,502,960 | - |
| | Term Loan Agrani Bank Ltd-UPAS LC | 71,452,594 | - |
| | | 15,302,215,365 | 13,073,034,212 |
| | Less: Current portion of long term loan (Note 21.1) | (277,157,666) | (201,882,832) |
| | | 15,025,057,699 | 12,871,151,380 |
| 21.1 Current portion of long term loan | | | |
| | Meridian Finance & Investment Ltd. | 5,391,952 | 12,119,184 |
| | Phoenix Finance & Investment Ltd. | 61,739,304 | 61,739,304 |
| | ODDO BHF AG Finance | 210,026,410 | 128,024,344 |
| | | 277,157,666 | 201,882,832 |
| 21.a Long term loan | | | |
| | Meridian Finance & Investment Ltd. | 5,391,952 | 13,356,974 |
| | Phoenix Finance & Investment Ltd. | 213,219,990 | 188,353,872 |
| | Agrani Bank Ltd. -BMRE | 3,578,186,261 | 3,078,758,648 |
| | Social Islami Bank Ltd | 1,000,605,285 | 938,069,748 |
| | AL-Arafa Islami Bank Ltd. | 1,870,458,262 | 1,776,578,444 |
| | ODDO BHF AG Finance | 840,105,642 | 576,109,548 |
| | Rupali Bank Ltd. | 673,268,517 | 618,126,543 |
| | SBLC-Cargill Financial Services International(CFSI) | 2,536,109,550 | - |
| | Term Loan Rupali Bank Ltd-UPAS LC | 87,502,960 | - |
| | Term Loan Agrani Bank Ltd-UPAS LC | 71,452,594 | - |
| | | 10,876,301,013 | 7,189,353,777 |
| | Less: Current portion of long term loan (Note 21.a.1) | (277,157,666) | (201,882,832) |
| | | 10,599,143,347 | 6,987,470,945 |

| SL No. | Particulars | Amount in Taka | |
|--------|-------------|----------------|-----------|
| | | 31-Mar-21 | 30-Jun-20 |

21.a.1 Current portion long term loan

| | | |
|------------------------------------|--------------------|--------------------|
| Meridian Finance & Investment Ltd. | 5,391,952 | 12,119,184 |
| Phoenix Finance & Investment Ltd. | 61,739,304 | 61,739,304 |
| ODDO BHF AG Finance | 210,026,410 | 128,024,344 |
| | 277,157,666 | 201,882,832 |

22 Lease obligation

| | | |
|--|-------------------|-------------------|
| Phoenix Finance & Investment Ltd. | 29,131,625 | 33,270,557 |
| Lease obligation (Office rent) | 51,339,645 | 51,984,423 |
| | 80,471,270 | 85,254,980 |
| Current portion of lease obligation (22.1) | (38,980,401) | (38,345,934) |
| | 41,490,869 | 46,909,046 |

22.1 Current portion of lease obligation

| | | |
|-----------------------------------|-------------------|-------------------|
| Phoenix Finance & Investment Ltd. | 15,457,560 | 15,457,560 |
| Lease obligation (Office rent) | 23,522,841 | 22,888,374 |
| | 38,980,401 | 38,345,934 |

23 Deferred tax liability

| | | |
|--|--------------------|--------------------|
| Opening balance | 142,611,072 | 98,226,477 |
| Adjustment for deferred tax expenses /(income) (Note-23.1) | 983,133 | 47,170,266 |
| Adjustment for deferred tax on revaluation surplus (Note-23.2) | (179,541) | (2,785,671) |
| | 143,414,664 | 142,611,072 |

23.1 Adjustment during the year on deferred tax on PPE

| | | |
|---|----------------|-------------------|
| Deferred tax liability on PPE (closing) | 93,879,711 | 92,896,578 |
| Deferred tax liability on PPE (opening) | 92,896,578 | 45,726,312 |
| Deferred tax expenses/(income) | 983,133 | 47,170,266 |

| Particular | WDV as at 31.03.2021 | | Amount in Taka | |
|---|----------------------|-----------------|---|---|
| | Tax Base | Accounting Base | Deferred Tax Liability as on 31.03.2021 | Deferred Tax Liability as on 30.06.2020 |
| Written down value of property, plant and equipment | 3,750,882,754 | 4,126,401,596 | (93,879,711) | (92,896,578) |

23.2 Adjustment of deferred tax on revaluation Surplus

| | | |
|---|------------------|--------------------|
| Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1) | 49,534,953 | 49,714,494 |
| Deferred tax liability on revaluation surplus (Opening) | 49,714,494 | 52,500,165 |
| Deferred tax expenses/(income) | (179,541) | (2,785,671) |

23.2.1 Adjustment of deferred tax on revaluation surplus

| Particulars | WDV as at 31.03.2021 | | Amount in Taka | |
|---|----------------------|----------------------|---|---|
| | Tax Base | Accounting Base | Deferred Tax Liability as on 31.03.2021 | Deferred Tax Liability as on 30.06.2020 |
| Revaluation reserved on land & land development | - | 1,298,728,729 | (38,961,862) | (38,961,862) |
| Revaluation reserved factory & office building | - | 62,606,327 | (9,390,949) | (10,152,377) |
| Revaluation reserved plant & machinery | - | 18,073,673 | (2,711,051) | (3,054,705) |
| Revaluation reserve on marketable securities | - | (15,289,090) | 1,528,909 | 2,454,451 |
| Total | - | 1,364,119,639 | (49,534,953) | (49,714,494) |

| SL No. | Particulars | Amount in Taka | |
|---|---|----------------------|----------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 24. Shot term loans | | | |
| | Cash credit (Hypo) Agrani Bank Ltd.,WASA Corp. Branch | 357,679,791 | 357,913,873 |
| | LTR Agrani Bank Ltd.,WASA Corporate Branch | 141,438,684 | 142,200,919 |
| | Loan against marketable securities | 64,833,693 | 65,880,930 |
| | | 563,952,168 | 565,995,722 |
| 25 Trade and other payables | | | |
| | Goods suppliers & manufacturer | 3,799,445,513 | 2,618,526,029 |
| | Other payable | 245,048,201 | 456,809,503 |
| | Current account with inter companies (Note -25.1) | 18,420,000 | 109,788,332 |
| | | 4,062,913,714 | 3,185,123,864 |
| 25.1 Current account with inter companies | | | |
| | Interior Accom Consortium Limited | - | 33,157,000 |
| | Orion Capital Ltd. | 18,420,000 | 18,420,000 |
| | Orion Power Rupsha Ltd. | - | 58,211,332 |
| | | 18,420,000 | 109,788,332 |
| 25.a Trade and other payables | | | |
| | Goods suppliers & manufacturer | 325,386,739 | 270,338,394 |
| | Other payables | 121,574,380 | 333,165,538 |
| | | 446,961,119 | 603,503,932 |
| 26 Employee benefits | | | |
| | Employee welfare fund (Note -26.1) | 7,028,277 | 6,567,966 |
| | Bangladesh workers welfare foundation (Note -26.2) | 13,056,373 | 8,892,117 |
| | Workers profit participation fund (Note -26.3) | 55,724,423 | 36,404,155 |
| | | 75,809,074 | 51,864,239 |
| 26.1 Employee welfare fund | | | |
| | Opening balance | 6,567,966 | 3,970,221 |
| | Add: Addition for the year | 4,164,256 | 3,977,650 |
| | Less: Payment during the year | (3,703,945) | (1,379,905) |
| | | 7,028,277 | 6,567,966 |
| 26.2 Bangladesh workers welfare foundation | | | |
| | Opening balance | 8,892,118 | 4,914,467 |
| | Add: Addition for the year | 4,164,256 | 3,977,650 |
| | | 13,056,373 | 8,892,117 |
| 26.3 Workers profit participation fund | | | |
| | Opening balance | 36,404,154 | 17,002,095 |
| | Add: Addition for the year | 33,314,047 | 31,821,206 |
| | Less: Payment during the year | (13,993,778) | (12,419,146) |
| | | 55,724,423 | 36,404,155 |
| 26.a Employee benefits | | | |
| | Employee welfare fund (Note -26.a.1) | 1,526,795 | 3,854,428 |
| | Bangladesh workers welfare foundation (Note -26.a.2) | 7,554,891 | 6,178,580 |
| | Workers profit participation fund (Note -26.a.3) | 11,712,565 | 14,695,850 |
| | | 20,794,252 | 24,728,858 |
| 26.a.1 Employee welfare fund | | | |
| | Opening Balance | 3,854,428 | 3,970,221 |
| | Addition during the year | 1,376,312 | 1,264,113 |
| | Payment during the year | (3,703,945) | (1,379,905) |
| | | 1,526,795 | 3,854,428 |

| SL No. | Particulars | Amount in Taka | |
|---------------|--|--------------------|--------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 26.a.2 | Bangladesh workers welfare foundation | | |
| | Opening balance | 6,178,580 | 4,914,467 |
| | Add: Addition for the year | 1,376,312 | 1,264,113 |
| | | 7,554,891 | 6,178,580 |
| 26.a.3 | Workers profit participation fund | | |
| | Opening Balance | 14,695,849 | 17,002,094 |
| | Addition during the year | 11,010,494 | 10,112,901 |
| | Payment during the year | (13,993,778) | (12,419,146) |
| | | 11,712,565 | 14,695,850 |
| | WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2018), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation". | | |
| 27. | Accrued expenses | | |
| | Salary and wages payable | 86,993,067 | 81,647,029 |
| | Director remuneration payable | 19,558,131 | 10,649,877 |
| | Depot expenses payable | 941,307 | 300,000 |
| | Telephone & mobile bill payable | 1,043,752 | 1,042,140 |
| | Payable for final settlement of employee | 8,849,355 | 7,507,047 |
| | Utilities payable | 5,933,990 | 2,172,517 |
| | Provision for income tax (Note 27.1) | 242,875,523 | 197,862,877 |
| | Corporate governance audit fees | - | 57,500 |
| | Statutory Audit fees | - | 1,265,000 |
| | Retention money | 1,132,380 | 3,618,657 |
| | Retirement benefit- P.F. | 3,618,657 | 34,048,932 |
| | Provision for gratuity | 38,959,870 | 21,622,489 |
| | Interest payable on Phonix Finance and Investment Ltd. | 20,822,303 | 2,279,198 |
| | Interest payable on Mashreq Dubai | 1,071,539 | 5,396,631 |
| | Interest payable on term loan | 5,644,726 | 5,692,894 |
| | Withholding VAT | 21,332,560 | 16,810,471 |
| | Withholding tax | 13,702,171 | 12,132,046 |
| | | 472,479,331 | 404,105,305 |
| 27.1 | Provision for income tax | | |
| | Opening balance | 197,862,877 | 188,622,950 |
| | Add: Addition during the year | 50,012,646 | 17,777,911 |
| | | 247,875,523 | 206,400,861 |
| | Less: Payment/AIT adjustment during the year | (5,000,000) | (8,537,984) |
| | | 242,875,523 | 197,862,877 |
| 27.a | Accrued expenses | | |
| | Salary and wages payable | 64,465,376 | 59,924,626 |
| | Director remuneration payable | 300,000 | 300,000 |
| | Depot expenses payable | 941,307 | 843,418 |
| | Telephone & mobile bill payable | 1,043,752 | 1,042,140 |
| | Payable for final settlement of employee | 8,849,355 | 7,507,047 |
| | Utilities payable | 5,933,990 | 2,172,517 |
| | Provision for income tax (Note - 27.a.1) | 242,875,522 | 197,862,877 |
| | Corporate governance audit fees | - | 57,500 |
| | Statutory Audit fees | - | 575,000 |
| | | 324,409,302 | 270,285,125 |

| SL No. | Particulars | Amount in Taka | |
|---------------|--|--------------------|--------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 27.a.1 | Provision for income tax | | |
| | Opening balance | 197,862,877 | 188,622,950 |
| | Add: Addition during the year | 50,012,646 | 17,777,911 |
| | | 247,875,522 | 206,400,861 |
| | Less: Payment/AIT adjustment during the year | (5,000,000) | (8,537,984) |
| | Closing balance | 242,875,522 | 197,862,877 |

| SL No. | Particulars | Amount in Taka | |
|------------|---|----------------------|----------------------|
| | | 31-Mar-21 | 31-Mar-20 |
| 28. | Revenue from net sales | | |
| | Local sales | 1,778,339,676 | 1,686,069,646 |
| | Export sales | 178,170,391 | 133,041,571 |
| | Revenue from power generation (Note-28.1) | 5,805,756,143 | 3,398,017,668 |
| | | 7,762,266,210 | 5,217,128,885 |

28.1 Revenue from power generation

| | | | |
|--|---|----------------------|----------------------|
| | Reference rental price | 1,984,413,601 | 1,762,540,000 |
| | Reference energy price (variable - O&M) | 152,172,503 | 65,452,568 |
| | HFO received from OOSL & BPDB | 3,685,187,111 | 1,580,695,049 |
| | Foreign exchange gain /(loss) | (16,017,071) | (10,669,949) |
| | | 5,805,756,143 | 3,398,017,668 |

28.a Revenue from net sales

| | | | |
|--|--------------|----------------------|----------------------|
| | Local sales | 1,778,339,676 | 1,686,069,646 |
| | Export sales | 178,170,391 | 133,041,571 |
| | | 1,956,510,067 | 1,819,111,217 |

29 Financial expense

| | | | |
|--|--|--------------------|--------------------|
| | Agrani Bank Limited, Cash Credit (H) - 48. | 23,635,923 | 23,956,158 |
| | Agrani Bank Limited, LTR | 10,101,738 | 8,416,350 |
| | Phoenix Finance & Investments Ltd. | 27,806,441 | 18,679,533 |
| | Meridian Finance & Investment Ltd. | 1,117,527 | 2,216,223 |
| | Finance cost on lease obligation (Office rent) | 3,231,262 | - |
| | Interest on Long Term Borrowing | 128,193,025 | 296,252,879 |
| | Bank Charge ,commission & Fees | 60,809,956 | 44,606,077 |
| | Interest on redeemable preference share | - | 84,286,324 |
| | Interest on loan- ILFSL | - | 32,541,804 |
| | Interest on Loan- BD Finance and Investment Ltd. | - | 9,748,737 |
| | | 254,895,872 | 520,704,086 |

29a Financial expenses

| | | | |
|--|--|-------------------|-------------------|
| | Agrani Bank Limited, Cash Credit (H) - 48. | 23,635,923 | 23,956,158 |
| | Agrani Bank Limited, LTR | 10,101,738 | 8,416,350 |
| | Phoenix Finance & Investments Ltd. | 27,644,363 | 18,421,537 |
| | Meridian Finance & Investment Ltd. | 1,117,527 | 2,216,223 |
| | Interest on loan- ILFSL | - | 32,541,804 |
| | Interest on Loan- BD Finance and Investment Ltd. | - | 9,748,737 |
| | Finance cost on lease obligation (Office rent) | 3,231,262 | - |
| | | 65,730,813 | 95,300,810 |

30. Current tax

| | | | |
|--|------------------------------|--------------------|--------------------|
| | Profit before tax | 275,262,353 | 221,674,018 |
| | Add: Accounting depreciation | 396,450,426 | 215,774,948 |
| | Less: Tax depreciation | (393,015,739) | (229,154,373) |
| | Taxable income | 278,697,040 | 208,294,593 |

| SL No. | Particulars | Amount in Taka | |
|--------|-------------|----------------|-----------|
| | | 31-Mar-21 | 30-Jun-20 |

Income tax provision

| Particulars | Taxable Income | Taxable Amount | |
|---|--------------------|-------------------|-------------------|
| | | 31-Mar-21 | 31-Mar-20 |
| 25% income tax on taxable profit | 235,486,761 | 58,871,690 | 47,848,225 |
| Half of 25% Income tax on export net profit | 25,066,879 | 3,133,360 | 2,026,529 |
| Cash Incentive from Export Sales | 13,898,400 | 3,474,600 | - |
| 20% income tax on dividend received | 4,245,000 | 849,000 | 137,892 |
| Total | 278,697,040 | 66,328,650 | 50,012,646 |

31 Earnings per share (EPS)

The computation is given below:

| | | |
|---|-------------|-------------|
| Net profit after tax | 696,296,098 | 643,759,394 |
| Ordinary shares outstanding during the year | 234,000,000 | 234,000,000 |
| Earning per share | 2.98 | 2.75 |

31a Earnings per share

The computation is given below:

| | | |
|---|-------------|-------------|
| Net profit after tax | 212,912,171 | 172,346,031 |
| Ordinary shares outstanding during the year | 234,000,000 | 234,000,000 |
| Earnings per share | 0.91 | 0.74 |

32. Net Assets Value (NAV) Per Share

| | | |
|---|----------------|----------------|
| Total Assets | 40,579,777,310 | 36,841,106,765 |
| Total Liabilities | 22,144,856,458 | 18,877,385,368 |
| Net Assets | 18,434,920,852 | 17,963,721,397 |
| No of shares | 234,000,000 | 234,000,000 |
| Net Assets Value (NAV) Per Share | 78.78 | 76.77 |

32a Net Assets Value (NAV) Per Share

| | | |
|---|----------------|----------------|
| Total Assets | 24,811,241,416 | 21,248,855,564 |
| Total Liabilities | 12,456,303,788 | 8,881,733,466 |
| Net Assets | 12,354,937,628 | 12,367,122,098 |
| No of shares | 234,000,000 | 234,000,000 |
| Net Assets Value (NAV) Per Share | 52.80 | 52.85 |

33. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:

| Particulars | 31-Mar-21 | 31-Mar-20 |
|--|----------------------|--------------------|
| Net profit before tax | 832,851,176 | 764,272,005 |
| Workers profit participation fund | 41,642,559 | 11,083,701 |
| Interest & other income | (29,910,237) | (2,041,264) |
| Financial expenses | 254,895,873 | 520,704,086 |
| Depreciation | 846,669,037 | 689,329,474 |
| Increase/(Decrease) in inventory | (377,172,008) | (624,848,275) |
| Increase/(Decrease) in receivables | (449,800,350) | (175,289,282) |
| Increase/(Decrease) in advance deposit & prepayments | (424,578,399) | (1,169,039,089) |
| Increase/(Decrease) in employee benefit | (17,697,724) | (13,799,051) |
| Increase/(Decrease) in payable | 1,100,921,898 | 668,565,074 |
| Increase/(Decrease) in accrued expenses | 28,711,314 | (16,225,264) |
| Income taxes paid | (47,689,344) | (14,429,663) |
| Net cash flow from operating Activities | 1,758,843,795 | 638,282,451 |
| Net operating cash flow per share | 7.52 | 2.73 |

| SL No. | Particulars | Amount in Taka | |
|--------------|--|-------------------|--------------------|
| | | 31-Mar-21 | 30-Jun-20 |
| 33.a | Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method: | | |
| | Particulars | 31-Mar-21 | 31-Mar-20 |
| | Net profit before tax | 275,262,353 | 221,674,018 |
| | Workers profit participation fund | 13,763,118 | 11,083,701 |
| | Interest & other income | (29,910,237) | (2,041,264) |
| | Financial expenses | 65,730,813 | 95,300,810 |
| | Depreciation | 396,450,426 | 215,774,948 |
| | Increase/(Decrease) in inventory | (75,494,505) | (91,709,921) |
| | Increase/(Decrease) in receivables | 2,378,208 | 8,131,336 |
| | Increase/(Decrease) in advance, deposit & prepayments | (472,561,974) | (324,330,925) |
| | Increase/(Decrease) in employee benefit | (17,697,724) | (13,799,051) |
| | Increase/(Decrease) in payable | (33,615,275) | 18,608,309 |
| | Increase/(Decrease) in accrued expenses | 9,111,532 | (16,225,264) |
| | Income taxes paid | (47,689,344) | (14,429,663) |
| | Net cash flow from operating activities | 85,727,391 | 108,037,034 |
| 33a.1 | Net operating cash flow per share | 0.37 | 0.46 |

Sd/- Chairman Sd/- Managing Director Sd/- Director Sd/- Chief Financial Officer Sd/- Company Secretary